- Home
- EVM vs VNDA Comparison
EVM vs VNDA Comparison
Compare EVM & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVM
- VNDA
- Stock Information
- Founded
- EVM 2002
- VNDA 2002
- Country
- EVM United States
- VNDA United States
- Employees
- EVM N/A
- VNDA N/A
- Industry
- EVM Finance/Investors Services
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- EVM Finance
- VNDA Health Care
- Exchange
- EVM Nasdaq
- VNDA Nasdaq
- Market Cap
- EVM 235.5M
- VNDA 249.4M
- IPO Year
- EVM N/A
- VNDA 2006
- Fundamental
- Price
- EVM $9.55
- VNDA $5.46
- Analyst Decision
- EVM
- VNDA Strong Buy
- Analyst Count
- EVM 0
- VNDA 2
- Target Price
- EVM N/A
- VNDA $16.50
- AVG Volume (30 Days)
- EVM 55.8K
- VNDA 503.6K
- Earning Date
- EVM 01-01-0001
- VNDA 11-05-2025
- Dividend Yield
- EVM 4.01%
- VNDA N/A
- EPS Growth
- EVM N/A
- VNDA N/A
- EPS
- EVM 0.20
- VNDA N/A
- Revenue
- EVM N/A
- VNDA $203,467,000.00
- Revenue This Year
- EVM N/A
- VNDA $15.45
- Revenue Next Year
- EVM N/A
- VNDA $37.82
- P/E Ratio
- EVM $47.61
- VNDA N/A
- Revenue Growth
- EVM N/A
- VNDA 11.78
- 52 Week Low
- EVM $7.67
- VNDA $3.81
- 52 Week High
- EVM $9.59
- VNDA $5.59
- Technical
- Relative Strength Index (RSI)
- EVM 67.29
- VNDA 67.52
- Support Level
- EVM $9.53
- VNDA $5.22
- Resistance Level
- EVM $9.74
- VNDA $5.48
- Average True Range (ATR)
- EVM 0.07
- VNDA 0.21
- MACD
- EVM -0.01
- VNDA 0.06
- Stochastic Oscillator
- EVM 37.59
- VNDA 90.31
About EVM Eaton Vance California Municipal Bond Fund of Beneficial Interest $.01 par value
Eaton Vance California Municipal Bond Fund is an investment company with an objective to provide current income exempt from regular federal income tax, including alternative minimum tax, and, in state specific funds, taxes in its specified state. The company provides its solutions to individual investors, institutional investors, high net worth individuals, family office investors, and financial professionals. It offers a range of equity, income, and alternative strategies to institutional investors, both in the United States and internationally.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.